Skip to main content
Publications
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A , Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial . Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438
Hauser RA, Sethi K, Klepitskaya O, Odak S , Joshi N, Kebede N, Olson K, Liang GS, Yonan C, Serbin M. Treatment patterns in a real-world sample of patients with parkinson's disease and motor fluctuations . Poster presented at the 146th 2021 American Neurological Association (ANA) Virtual Meeting; October 17, 2021. [abstract] Ann Neurol. 2021 Oct; 90(S27):S153.
Pujol J, Fenoll R, Forns J , Harrison BJ, Martinez-Vilavella G, Macia D, Alvarez-Pedrerol M, Blanco-Hinojo L, Gonzalez-Ortiz S, Deus J, Sunyer J. Video gaming in school children: how much is enough? Ann Neurol. 2016 Sep;80(3):424-33. doi: 10.1002/ana.24745
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ , Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers . Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470
Shafi MM, Vernet M, Klooster D, Chu CJ, Boric K , Barnard ME, Romatoski K, Westover MB, Christodoulou JA, Gabrieli JDE, Whitfield-Gabrieli S, Pascual-Leone A, Chang BS. Physiological consequences of abnormal connectivity in a developmental epilepsy . Ann Neurol. 2015 Mar;77(3):487-503. doi: 10.1002/ana.24343
Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L , Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial . Cancer. 2013 Mar 15;119(10):1908-15.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X , Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas . Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111